The Latest Cardiac and Vascular News
— Considered as the industry’s equivalent of the Nobel Prize in biopharmaceutical and medical technology research, Prix Galien USA honored MitraClip as the Best Medical Technology for 2020 — The groundbreaking MitraClip therapy has positively impacted the lives of more than 100,000 people globally living with mitral regurgitation, or a […]
BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a non-exclusive royalty-bearing license agreement with Abbott Laboratories (NYSE: ABT), the global healthcare company. The non-exclusive license grants Abbott access to Quanterix’ portfolio of bead-based technology […]
– CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology – MitraClip is a first-of-its-kind transcatheter mitral valve therapy, now on its fourth generation, improving further on MitraClip’s history as a safe and effective treatment option ABBOTT […]
– The LIFE-BTK trial will evaluate the company’s new drug-eluting resorbable scaffold (DRS), known as the Esprit BTK System, for the treatment of blocked arteries below-the-knee (BTK) – Esprit BTK was granted breakthrough device designation by the U.S. FDA – There are no stents or drug-coated balloons currently approved for […]
– Recurrent irregular heartbeat–also known as atrial fibrillation–impacts more than 16 million people globally – Trial supports Abbott’s focus on being the best partner for electrophysiologists treating people living with atrial fibrillation ABBOTT PARK, Ill., Aug. 4, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced first enrollments in the TactiFlex PAF IDE study to […]
ABBOTT PARK, Ill., July 13, 2020 /PRNewswire/ — Abbott (NYSE: ABT) announced today it has reached an agreement with Edwards Lifesciences Corporation to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. The agreement will result in the dismissal of all pending cases or appeals […]
ABBOTT PARK, Ill., July 6, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The devices bring new benefits to patients with heart rhythm disorders, including […]
— Using optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI), physicians were able to select the right size stents and place them with greater precision — Imaging techniques such as OCT have been shown to improve outcomes during stenting procedures¹, but remain underutilized in global clinical settings due to lack […]
– New data reinforce Abbott’s leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies – Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott’s innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings ABBOTT PARK, Ill., June […]
– First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent – Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19) ABBOTT PARK, Ill., April 16, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2020. First-quarter worldwide sales of $7.7 billion increased 2.5 percent on […]
